Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has been described with cyclophosphamide-prednisone...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Franssen, Laurens E., Nijhof, Inger S., Bjorklund, Chad C., Chiu, Hsiling, Doorn, Ruud, van Velzen, Jeroen, Emmelot, Maarten, van Kessel, Berris, Levin, Mark-David, Bos, Gerard M.J., Broijl, Annemiek, Klein, Saskia K., Koene, Harry R., Bloem, Andries C., Beeker, Aart, Faber, Laura M., van der Spek, Ellen, Raymakers, Reinier, Sonneveld, Pieter, Zweegman, Sonja, Lokhorst, Henk M., Thakurta, Anjan, Qian, Xiaozhong, Mutis, Tuna, van de Donk, Niels W.C.J.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188055/
https://ncbi.nlm.nih.gov/pubmed/30338042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados